The Place of Sugammadex in Neuromuscular Block Reversal in Clinical Settings
| dc.contributor.advisor | Pórszász, Róbert | |
| dc.contributor.advisordept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.author | Hamad, Mussa | |
| dc.contributor.department | DE--Általános Orvostudományi Kar | hu_HU |
| dc.contributor.opponent | Szentmiklósi, József András | |
| dc.contributor.opponent | Drimba, László | |
| dc.contributor.opponentdept | Debreceni Egyetem::Általános Orvostudományi Kar::Farmakológiai és Farmakoterápiai Intézet | hu_HU |
| dc.contributor.opponentdept | Kenézy Kórház Aneszteziológiai és Intenziv Therápiás Osztály | hu_HU |
| dc.date.accessioned | 2015-12-29T09:42:21Z | |
| dc.date.available | 2015-12-29T09:42:21Z | |
| dc.date.created | 2015 | |
| dc.description.abstract | The thesis gives a general review on agents used for neuromuscular junction blockage and their reversal in clinical settings. The thesis focuses mainly on the new drug sugammadex which opens a new category of neuromuscular junction block reversal due to unique mode of action. It has been approved by the FDA only recently (15th of December 2015), and in this thesis I compare various studies highlighting it's benefits and disadvantages. | hu_HU |
| dc.description.course | általános orvos | hu_HU |
| dc.description.courselang | angol | hu_HU |
| dc.description.degree | egységes, osztatlan | hu_HU |
| dc.format.extent | 39 | hu_HU |
| dc.identifier.uri | http://hdl.handle.net/2437/220853 | |
| dc.language.iso | en | hu_HU |
| dc.subject | Sugammadex | hu_HU |
| dc.subject | Neuromuscular block reversal | hu_HU |
| dc.subject | Neuromuscular Junction | hu_HU |
| dc.subject | Anesthesiology | hu_HU |
| dc.subject | rocuronium | hu_HU |
| dc.subject.dspace | DEENK Témalista::Orvostudomány | hu_HU |
| dc.title | The Place of Sugammadex in Neuromuscular Block Reversal in Clinical Settings | hu_HU |